Development and validation of a LC–MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. (July 2017) - Zangarini, Monique
Aim: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC–MS/MS method for quantifying plasma concentrations of SRA737 was validated.Methods & results: Sample preparation involved protein precipitation with acetonitrile following addition of 13 C 15 N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5–20, 000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96–102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml.Conclusion: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.